175 related articles for article (PubMed ID: 29339434)
1. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis.
Malhotra K; Katsanos AH; Bilal M; Ishfaq MF; Goyal N; Tsivgoulis G
Stroke; 2018 Feb; 49(2):312-318. PubMed ID: 29339434
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
3. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
4. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis.
Malhotra K; Goyal N; Kasunich AS; Sheth SA; Katsanos AH; Alexandrov AV; Tsivgoulis G
J Neurol Sci; 2018 Jul; 390():212-218. PubMed ID: 29801891
[TBL] [Abstract][Full Text] [Related]
8. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.
Melloni C; Washam JB; Jones WS; Halim SA; Hasselblad V; Mayer SB; Heidenfelder BL; Dolor RJ
Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):47-55. PubMed ID: 25587094
[TBL] [Abstract][Full Text] [Related]
9. Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel.
Li S; Liu F; Chen C; Zhu W; Ma J; Hu J; Xu J; Hong K
Int Heart J; 2019 Jul; 60(4):910-918. PubMed ID: 31308328
[TBL] [Abstract][Full Text] [Related]
10. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
[TBL] [Abstract][Full Text] [Related]
11. Association of the use of proton pump inhibitors with adverse cardiovascular and bleeding outcomes after percutaneous coronary intervention in the Japanese real world clinical practice.
Kimura T; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Tatami R; Suwa S; Takizawa A; Takatsu Y; Takahashi M; Kato H; Takeda T; Lee JD; Nohara R; Tei C; Horie M; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T
Cardiovasc Interv Ther; 2011 Sep; 26(3):222-33. PubMed ID: 24122589
[TBL] [Abstract][Full Text] [Related]
12. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
13. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
[TBL] [Abstract][Full Text] [Related]
14. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.
Wang YF; Chen YT; Luo JC; Chen TJ; Wu JC; Wang SJ
Am J Gastroenterol; 2017 Jul; 112(7):1084-1093. PubMed ID: 28397874
[TBL] [Abstract][Full Text] [Related]
15. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.
Khan SU; Lone AN; Asad ZUA; Rahman H; Khan MS; Saleem MA; Arshad A; Nawaz N; Sattur S; Kaluski E
Cardiovasc Revasc Med; 2019 Dec; 20(12):1125-1133. PubMed ID: 30773427
[TBL] [Abstract][Full Text] [Related]
17. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
[TBL] [Abstract][Full Text] [Related]
18. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Ho PM; Maddox TM; Wang L; Fihn SD; Jesse RL; Peterson ED; Rumsfeld JS
JAMA; 2009 Mar; 301(9):937-44. PubMed ID: 19258584
[TBL] [Abstract][Full Text] [Related]
19. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
20. No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication.
Nguyen LH; Lochhead P; Joshi AD; Cao Y; Ma W; Khalili H; Rimm EB; Rexrode KM; Chan AT
Gastroenterology; 2018 Apr; 154(5):1290-1297.e1. PubMed ID: 29269313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
